ABIOMED INC (ABMD) Stock Fundamental Analysis
USA - NASDAQ:ABMD - US0036541003 - Common Stock
381.02 USD
+0.23 (+0.06%)
381.3 USD
+0.28 (+0.07%)
Overall ABMD gets a fundamental rating of 7 out of 10. We evaluated ABMD against 189 industry peers in the Health Care Equipment & Supplies industry. ABMD has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. ABMD is not valued too expensively and it also shows a decent growth rate. With these ratings, ABMD could be worth investigating further for quality investing!.
1. Profitability
1.1 Basic Checks
In the past year ABMD was profitable.
In the past year ABMD had a positive cash flow from operations.
ABMD had positive earnings in each of the past 5 years.
ABMD had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
ABMD has a better Return On Assets (15.72%) than 94.52% of its industry peers.
ABMD has a better Return On Equity (17.32%) than 93.61% of its industry peers.
ABMD has a better Return On Invested Capital (12.19%) than 89.95% of its industry peers.
The Average Return On Invested Capital over the past 3 years for ABMD is significantly above the industry average of 9.02%.
The 3 year average ROIC (29.16%) for ABMD is well above the current ROIC(12.19%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.72% | ||
| ROE | 17.32% | ||
| ROIC | 12.19% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)29.16%
ROIC(5y)N/A
1.3 Margins
ABMD has a better Profit Margin (24.84%) than 95.43% of its industry peers.
ABMD's Profit Margin has improved in the last couple of years.
The Operating Margin of ABMD (23.66%) is better than 93.61% of its industry peers.
ABMD's Operating Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 23.66% | ||
| PM (TTM) | 24.84% | ||
| GM | N/A |
OM growth 3Y-5.22%
OM growth 5Y4.22%
PM growth 3Y-26.75%
PM growth 5Y2.49%
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ABMD has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for ABMD has been increased compared to 1 year ago.
There is no outstanding debt for ABMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
ABMD has an Altman-Z score of 68.47. This indicates that ABMD is financially healthy and has little risk of bankruptcy at the moment.
ABMD has a better Altman-Z score (68.47) than 99.54% of its industry peers.
There is no outstanding debt for ABMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 68.47 |
ROIC/WACC1.34
WACC9.07%
2.3 Liquidity
A Current Ratio of 7.93 indicates that ABMD has no problem at all paying its short term obligations.
ABMD has a Current ratio of 7.93. This is amongst the best in the industry. ABMD outperforms 83.11% of its industry peers.
A Quick Ratio of 7.17 indicates that ABMD has no problem at all paying its short term obligations.
ABMD has a better Quick ratio (7.17) than 82.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.93 | ||
| Quick Ratio | 7.17 |
3. Growth
3.1 Past
ABMD shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.78%.
The Earnings Per Share has been growing by 30.92% on average over the past years. This is a very strong growth
ABMD shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.32%.
Measured over the past years, ABMD shows a quite strong growth in Revenue. The Revenue has been growing by 18.30% on average per year.
EPS 1Y (TTM)-3.78%
EPS 3Y-2.48%
EPS 5Y30.92%
EPS Q2Q%26.21%
Revenue 1Y (TTM)10.32%
Revenue growth 3Y10.27%
Revenue growth 5Y18.3%
Sales Q2Q%7.16%
3.2 Future
ABMD is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.71% yearly.
Based on estimates for the next years, ABMD will show a quite strong growth in Revenue. The Revenue will grow by 11.13% on average per year.
EPS Next Y3.83%
EPS Next 2Y9.68%
EPS Next 3Y14%
EPS Next 5Y15.71%
Revenue Next Year10.29%
Revenue Next 2Y12.97%
Revenue Next 3Y13.62%
Revenue Next 5Y11.13%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 78.72, which means the current valuation is very expensive for ABMD.
Compared to the rest of the industry, the Price/Earnings ratio of ABMD indicates a somewhat cheap valuation: ABMD is cheaper than 71.69% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 26.11. ABMD is valued rather expensively when compared to this.
Based on the Price/Forward Earnings ratio of 66.96, the valuation of ABMD can be described as expensive.
Based on the Price/Forward Earnings ratio, ABMD is valued a bit cheaper than the industry average as 73.06% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 22.55. ABMD is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 78.72 | ||
| Fwd PE | 66.96 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ABMD is valued a bit cheaper than the industry average as 69.41% of the companies are valued more expensively.
80.82% of the companies in the same industry are more expensive than ABMD, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 79.09 | ||
| EV/EBITDA | 55.82 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates ABMD does not grow enough to justify the current Price/Earnings ratio.
ABMD has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as ABMD's earnings are expected to grow with 14.00% in the coming years.
PEG (NY)20.54
PEG (5Y)2.55
EPS Next 2Y9.68%
EPS Next 3Y14%
5. Dividend
5.1 Amount
ABMD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
381.02
+0.23 (+0.06%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners0%
Inst Owner Change0%
Ins Owners1.66%
Ins Owner Change0%
Market Cap17.18B
Revenue(TTM)1.07B
Net Income(TTM)266.76M
Analysts70
Price Target375.36 (-1.49%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.37%
Min EPS beat(2)-5.24%
Max EPS beat(2)15.98%
EPS beat(4)3
Avg EPS beat(4)8.26%
Min EPS beat(4)-5.24%
Max EPS beat(4)15.98%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-14.37%
Min Revenue beat(2)-16.89%
Max Revenue beat(2)-11.85%
Revenue beat(4)0
Avg Revenue beat(4)-11.39%
Min Revenue beat(4)-16.89%
Max Revenue beat(4)-6.39%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)19.09%
PT rev (3m)N/A
EPS NQ rev (1m)4.13%
EPS NQ rev (3m)N/A
EPS NY rev (1m)1.46%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)-3.26%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-1.36%
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 78.72 | ||
| Fwd PE | 66.96 | ||
| P/S | 16 | ||
| P/FCF | 79.09 | ||
| P/OCF | 68.45 | ||
| P/B | 11.16 | ||
| P/tB | 12.15 | ||
| EV/EBITDA | 55.82 |
EPS(TTM)4.84
EY1.27%
EPS(NY)5.69
Fwd EY1.49%
FCF(TTM)4.82
FCFY1.26%
OCF(TTM)5.57
OCFY1.46%
SpS23.82
BVpS34.15
TBVpS31.36
PEG (NY)20.54
PEG (5Y)2.55
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.72% | ||
| ROE | 17.32% | ||
| ROCE | N/A | ||
| ROIC | 12.19% | ||
| ROICexc | 25.66% | ||
| ROICexgc | 30.76% | ||
| OM | 23.66% | ||
| PM (TTM) | 24.84% | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)29.16%
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y-10.63%
ROICexgc growth 5Y-2.2%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-5.22%
OM growth 5Y4.22%
PM growth 3Y-26.75%
PM growth 5Y2.49%
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 122.5% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | 81.43% | ||
| Current Ratio | 7.93 | ||
| Quick Ratio | 7.17 | ||
| Altman-Z | 68.47 |
F-Score6
WACC9.07%
ROIC/WACC1.34
Cap/Depr(3y)188.19%
Cap/Depr(5y)276.96%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)138.14%
Profit Quality(5y)123.31%
High Growth Momentum
Growth
EPS 1Y (TTM)-3.78%
EPS 3Y-2.48%
EPS 5Y30.92%
EPS Q2Q%26.21%
EPS Next Y3.83%
EPS Next 2Y9.68%
EPS Next 3Y14%
EPS Next 5Y15.71%
Revenue 1Y (TTM)10.32%
Revenue growth 3Y10.27%
Revenue growth 5Y18.3%
Sales Q2Q%7.16%
Revenue Next Year10.29%
Revenue Next 2Y12.97%
Revenue Next 3Y13.62%
Revenue Next 5Y11.13%
EBIT growth 1Y-2.58%
EBIT growth 3Y4.52%
EBIT growth 5Y23.29%
EBIT Next Year13.8%
EBIT Next 3Y20.3%
EBIT Next 5Y16.96%
FCF growth 1Y-11.7%
FCF growth 3Y6.24%
FCF growth 5Y31%
OCF growth 1Y-11.94%
OCF growth 3Y4.21%
OCF growth 5Y19.91%
ABIOMED INC / ABMD FAQ
What is the fundamental rating for ABMD stock?
ChartMill assigns a fundamental rating of 6 / 10 to ABMD.
Can you provide the valuation status for ABIOMED INC?
ChartMill assigns a valuation rating of 0 / 10 to ABIOMED INC (ABMD). This can be considered as Overvalued.
Can you provide the profitability details for ABIOMED INC?
ABIOMED INC (ABMD) has a profitability rating of 6 / 10.
Can you provide the PE and PB ratios for ABMD stock?
The Price/Earnings (PE) ratio for ABIOMED INC (ABMD) is 78.72 and the Price/Book (PB) ratio is 11.16.